E²-RADIatE will be activated gradually in radiotherapy centres in Europe. In the first phase, sites will be activated between April and September 2019.
Patient recruitment will then be possible for patients eligible for the OligoCare cohort. After evaluation of the first phase, we will proceed to the next phase and open more countries and sites. In the second phase, patient recruitment is expected to be also possible for patients eligible for the ParticleCare cohort.
Some general principles apply to the activation of E²-RADIatE:
- Interested sites will be activated for the E²-RADIatE protocol after regulatory approval. After activation, the site can recruit patients in one or more cohorts depending on site choice.
- Principle investigators are cohort specific. This means that a site can have more than 1 principal investigator for the E²-RADIatE study.
- The principle investigator should be either an EORTC or ESTRO member.